ライフサイエンスコーパス: dipyridamole

1 er clopidogrel alone or combined aspirin and dipyridamole).

2 brative nucleoside transporter (ENT) blocker dipyridamole.

3 ke of (3)H-adenosine, which was inhibited by dipyridamole.

4 and during hyperemia induced by intravenous dipyridamole.

5 monocytes, a response that was inhibited by dipyridamole.

6 ibited nearly 100% by the presence of 80 muM dipyridamole.

7 perfusion at rest and that after infusion of dipyridamole.

8 onductance that is blocked by substrates and dipyridamole.

9 by blocking the nucleoside transporter with dipyridamole.

10 ) were measured at rest and after 0.56 mg/kg dipyridamole.

11 after coronary vasodilation with intravenous dipyridamole.

12 igher in both beds with dobutamine than with dipyridamole.

13 s test is not less than hyperemia induced by dipyridamole.

14 s those demonstrating an MBF reserve <3 with dipyridamole.

15 eers at rest and after hyperemic stress with dipyridamole.

16 with 13NH3 at rest and after infusion of IV dipyridamole.

17 Rest/stress scanning was performed using dipyridamole.

18 cleoside analogs, hypoxanthine, guanine, and dipyridamole.

19 s to be oxidative stress that is relieved by dipyridamole.

20 t were rescued in large measure by 10 microM dipyridamole.

21 s autophagy induction were also inhibited by dipyridamole.

22 ed functional studies with the ENT inhibitor dipyridamole.

23 compound and the fluorescent energy acceptor dipyridamole.

24 ide transporter 1, which can be inhibited by dipyridamole.

25 of 0.49 nM compared to a K(i) of 308 nM for dipyridamole.

26 , and PET to quantify resting and hyperemic (dipyridamole 0.56 mg/kg) MBF and CVR in both the subendo

27 1, we compared the effects of iNO (20 ppm), dipyridamole (0.6 mg/kg), and combined treatments (iNO +

28 atheter before, during and after infusion of dipyridamole (142 microg/kg body weight per min for 4 mi

29 scans) and 41 after coronary hyperemia with dipyridamole (17 82Rb scans, 17 H2(15)O scans, and 7 13N

30 The adenosine transport inhibitors, dipyridamole (2 microM) and S-(4-nitorobenzyl)-6-thioino

31 mbined aspirin 75 mg, clopidogrel 75 mg, and dipyridamole 200 mg twice daily) or guideline-based ther

32 ICB microinjection of dipyridamole (25 microg), an adenosine transport inhibit

33 c events occurred in 6 patients on ASA 81 mg+dipyridamole (26%; 0.42 events per patient year; mean IN

34 injected intraperitoneally with 50 mg/kg of dipyridamole 3 times a week for 3 weeks.

35 ion of a 0.56 mg/kg dose of the vasodilator, dipyridamole, 3 serial whole-body PET scans were acquire

36 fusion and CFR after adenosine compared with dipyridamole, (4) heterogeneity of coronary flow capacit

37 ere categorized into 3 groups: (1) ASA 81 mg+dipyridamole 75 mg daily (n = 26) with a target internat

38 Dipyridamole 75 mg was administered orally three times d

39 disease, 275 individuals had undergone rest-dipyridamole (82)Rb myocardial perfusion imaging using P

40 nts underwent PET/CT, consisting of rest and dipyridamole (82)Rb perfusion studies and contrast-enhan

41 zed 265 subjects who underwent clinical rest-dipyridamole (82)Rb PET/CT.

42 to undergo either both an early (day 2 to 4) dipyridamole (99m)Tc-sestamibi MPI study and a predischa

43 Dipyridamole, a drug with several putative vasodilator m

44 ke was inhibitable by Ned-19, a NAADP mimic; dipyridamole, a nucleoside inhibitor; or NaN3, a metabol

45 BAY60-6583 and dipyridamole, a nucleoside transport inhibitor, stimulat

46 yocardium and that this can be overcome with dipyridamole, a nucleoside transporter blocker.

47 Dipyridamole, a pharmaceutical agent used for the first

48 Selected cells were exposed to caffeine, dipyridamole, adenosine 5'-(alpha,beta-methylene)diphosp

49 ng exercise, pharmacologic stress (including dipyridamole, adenosine, dobutamine, and arbutamine), or

50 t (largely endothelium-dependent), and after dipyridamole administration (largely vascular smooth mus

51 Treatment of MRL/lpr mice with dipyridamole alleviated lupus nephritis and prevented th

52 y decreased PVRI by 20% more than did iNO or dipyridamole alone.

53 Dipyridamole also blocked MCP-1 and MMP-9 generated by l

54 viability was almost totally recovered with dipyridamole, an adenosine transporter inhibitor.

55 However, preexposure of SKOV-3 cells to dipyridamole, an equilibrative nucleoside transporter in

56 In addition, treatment of these models with dipyridamole, an inhibitor of nucleoside transporters th

57 For the first time, a dipyridamole analogue has been identified that is equipo

58 A series of dipyridamole analogues were synthesized with systematic

59 Dipyridamole and adenosine cause frequent side effects a

60 a dominant role in conferring sensitivity to dipyridamole and adenosine/guanosine affinity.

61 of (3)H-AMP was only partially inhibited by dipyridamole and APCP.

62 e of (3)H-AMP was significantly inhibited by dipyridamole and APCP.

63 aspirin, ticlopidine, and the combination of dipyridamole and aspirin are associated with a significa

64 Here, we determined whether dipyridamole and aspirin, a combination therapy used to

65 Replicative amplification promoted by dipyridamole and dilazep were dependent on HSV mutations

66 Two of these compounds, dipyridamole and dilazep, interfered with nucleotide met

67 Both dipyridamole and dobutamine are used clinically as pharm

68 Although the effects of dipyridamole and dobutamine on MBV and VEL are different

69 e hypothesized that, although the effects of dipyridamole and dobutamine on myocardial blood volume (

70 f the ENT1 nucleoside transporter inhibitors dipyridamole and NBTI and were significantly inhibited b

71 he classic nucleoside transporter inhibitors dipyridamole and nitrobenzylmercaptopurine ribonucleosid

72 'leak' cation fluxes were inhibited by SITS, dipyridamole and NS1652, chemically diverse inhibitors o

73 Ticagrelor, dipyridamole and the active metabolite of clopidogrel (C

74 The hyperemic response to dipyridamole and the myocardial flow reserve did not dif

75 ent in Group 1 had a hypotensive response to dipyridamole and was exluded from study.

76 with IC(50) values of 0.82 and 5 microM for dipyridamole and zaprinast, respectively.

77 2823 patients taking aspirin (alone or with dipyridamole) and by 269 (11.0%) of 2446 in the control

78 including rolipram, vinpocetine, SKF-94120, dipyridamole, and 3-isobutyl-1-methyl-xanthine but is in

79 tment with two specific inhibitors of AICAR, dipyridamole, and 5-iodotubericidin.

80 transport inhibitors nitrobenzylthioinosine, dipyridamole, and dilazep and was sodium ion-independent

81 at viral protein synthesis was unaffected by dipyridamole, and rather, RNA synthesis was the step tar

82 It is also inhibited by papaverine, dipyridamole, and SCH51866 at higher doses.

83 en-chest dogs with acute coronary occlusion, dipyridamole (approximately 0.56 mg/kg) was infused intr

84 Adenosine (Ado) and dipyridamole are alternatives to exercise stress for myo

85 Adenosine and dipyridamole are nonselective adenosine agonists current

86 ogeneity analysis, and its improvement after dipyridamole, are powerful independent predictors of eve

87 elet regimens--aspirin plus extended-release dipyridamole (ASA-ERDP) versus clopidogrel.

88 platelets and monocytes were pretreated with dipyridamole, aspirin, or both inhibitors.

89 cebo group and 28% (95% CI, 23 to 34) in the dipyridamole-aspirin group, an absolute difference of 5

90 placebo-controlled trial of extended-release dipyridamole, at a dose of 200 mg, and aspirin, at a dos

91 increase in CI; (2) in combination with iNO, dipyridamole augments the decrease in PVRI in some patie

92 asal NO release, we measured the response to dipyridamole before and after pretreatment with the NO s

93 rst time interaction of Met(33) (involved in dipyridamole binding) with BCR-ABL inhibitors and reduce

94 eviously shown to be involved in uridine and dipyridamole binding, suggested that BCR-ABL TKIs intera

95 Dipyridamole blunted the feedback response, which upregu

96 Pretreatment with dipyridamole blunted the increase in Ppa and Rp/Rs durin

97 e decrease in PVRI in some patients; and (3) dipyridamole blunts the severity of acute hypoxic pulmon

98 -3 uptake of (3)H-adenosine was inhibited by dipyridamole but not APCP.

99 Dipyridamole but not aspirin attenuated nuclear transloc

100 rinast (by 12.0+/-4.7 min [mean +/- SEM]) or dipyridamole (by 9.8+/-4.7 min).

101 We propose that dipyridamole can be used in treatment regimens for patie

102 Dipyridamole cardiac MR imaging can be used to predict M

103 es were recorded, 90 subjects underwent rest-dipyridamole cardiac PET perfusion imaging, including 18

104 mbined with specially formulated long-acting dipyridamole carries a lower risk of stroke than aspirin

105 Dipyridamole caused an increase (mean, 21%) in the rate-

106 The statin-dipyridamole combination was synergistic and induced apo

107 reference subjects and its improvement with dipyridamole correlated closely with CAD documented by s

108 Dipyridamole decreased PVRI to similar values as did iNO

109 Dipyridamole delayed maximal synthesis of interleukin-8

110 Notably, dipyridamole-dependent attenuation of lung inflammation

111 In this case, however, dipyridamole did not block transcription or distribution

112 ; mRS shift OR 0.90, 0.37-1.72, p=0.99), but dipyridamole did reduce risk thereafter (0.76, 0.63-0.92

113 dividual treatments, combined therapy (iNO + dipyridamole) did not augment pulmonary vasodilation in

114 itors of equilibrative nucleoside transport, dipyridamole, dilazep, and nitrobenzylthioinosine.

115 ng handgripping before and after infusion of dipyridamole (DIP) in 20 subjects.

116 The cardiovascular and antithrombotic agent dipyridamole (DP) has potential therapeutic utility as a

117 Rest and dipyridamole (DP)-stress 99mTc sestamibi single-photon e

118 (5 and 20 ppm) alone and in combination with dipyridamole during mechanical ventilation with low FlO2

119 1680 (A2AR agonist, EC50 = 160 nM), or 1 muM dipyridamole (EC50 = 32 nM) promoted bone regeneration.

120 rection (MAC) scans, followed by resting and dipyridamole emission scans; (b). an initial MAC scan (e

121 Intravenous dipyridamole enhanced resting muscle dialysate adenosine

122 In contrast, extended-release dipyridamole (ER-DP) plus aspirin reduces secondary stro

123 Membrane drug content in patients taking dipyridamole for other clinical indications was similar

124 Blockade of adenosine transport (by NBTI/dipyridamole) had inconsistent effects on basal levels o

125 These results indicate that dipyridamole has selective antiinflammatory properties t

126 nd the contrasting time course of effects of dipyridamole have implications for understanding mechani

127 Dipyridamole, however, an inhibitor that is generally co

128 ith (13)N-ammonia and PET at rest and during dipyridamole hyperemia in 36 patients with coronary risk

129 uring cold pressor testing (CPT), and during dipyridamole hyperemia in 54 postmenopausal women withou

130 .4 +/- 0.1 nM versus 2.8 +/- 0.3 microM) and dipyridamole (IC(50), 5.0 +/- 0.9 nM versus 356 +/- 13 n

131 hesis, we studied the hemodynamic effects of dipyridamole in 19 late-gestation fetal lambs.

132 ded warfarin in 68.3%, aspirin in 55.7%, and dipyridamole in 58.2% of the patients.

133 he recently recognized calcineurin inhibitor dipyridamole in limiting SLE-related pathology.

134 The normal hyperemic response to dipyridamole in long-term smokers indicates a preserved

135 g blood flow) is induced by intravenous (IV) dipyridamole in patients with severe coronary artery dis

136 e interaction between effects of aspirin and dipyridamole in secondary prevention of stroke.

137 To test dipyridamole in the pulmonary circulation, we studied pe

138 at rest to 68 +/- 27 ml/100 g/min following dipyridamole in the segments with steal, and increased f

139 +/- 19 to 138 +/- 16 ml/100 g/min following dipyridamole in the segments without steal.

140 thout concomitant administration of low-dose dipyridamole, in six fetal lambs.

141 Dipyridamole increases adenosine bioavailability.

142 flow was unchanged during vasodilation with dipyridamole, indicating the increases in collateral flo

143 prolonged (2-h) infusions, acetylcholine and dipyridamole individually caused transient pulmonary vas

144 e model of regional myocardial ischemia with dipyridamole induced hyperemia, 201Tl shows a more ideal

145 The dipyridamole-induced change in the apparent transverse r

146 Dipyridamole-induced coronary hyperemia produces mild he

147 ified as the strongest predictor of impaired dipyridamole-induced hyperemia and flow reserve in our s

148 ndothelium-dependent vasomotion), and during dipyridamole-induced hyperemia in 16 long-term smokers a

149 of quantitative, statistically significant, dipyridamole-induced myocardial perfusion abnormalities

150 g with CAD (first-degree relatives), 50% had dipyridamole-induced myocardial perfusion defects that i

151 artery disease without significant segmental dipyridamole-induced myocardial perfusion defects, we te

152 We conclude that dipyridamole-induced pulmonary vasodilation is dependent

153 L-NA completely blocked dipyridamole-induced pulmonary vasodilation.

154 blood flow (MBF) reserve is the mechanism of dipyridamole-induced regional dysfunction in chronic cor

155 dial MBF reserve is the primary mechanism of dipyridamole-induced regional dysfunction in chronic cor

156 ic disease without statistically significant dipyridamole-induced segmental myocardial perfusion defe

157 hat was also observed for moderate to severe dipyridamole-induced segmental perfusion defects (P=0.00

158 , and EDV were calculated at rest and during dipyridamole-induced stress, using CardIQ Physio (a dedi

159 The dipyridamole-induced total vasodilator capacity was sign

160 To determine whether dipyridamole-induced vasodilation is dependent upon basa

161 Quantitative severity of dipyridamole-induced, circumscribed, segmental PET perfu

162 rdial perfusion were measured at rest, after dipyridamole infusion (0.56 mg x kg(-1)), and at peak do

163 wn that HCM patients have impaired MBF after dipyridamole infusion and that this blunted MBF is a pow

164 of this study were to examine the effects of dipyridamole infusion on hemodynamic variables and to co

165 Ticagrelor and dipyridamole inhibit platelet function by inhibiting P2Y

166 hese cells, our study also demonstrates that dipyridamole-inhibitable transport of adenosine into the

167 At 2% hematocrit, 10 microM dipyridamole inhibited 65% of the increase in net fluxes

168 In addition, dipyridamole inhibited the Ca(++)-activated K(+) flux (v

169 We further show that dipyridamole inhibited the cleavage of the transcription

170 w similar dose response curves for NBMPR and dipyridamole inhibition of [(3)H]adenosine uptake as wel

171 red with wild-type hENT1, the sensitivity to dipyridamole inhibition was significantly (p < 0.05) inc

172 ray of compounds that mimic other actions of dipyridamole (inhibition of phosphodiesterases, blockade

173 Dipyridamole inhibits SLE T cell function and improves p

174 Dipyridamole is a good candidate for further exploration

175 We conclude that dipyridamole is a potent experimental tool that readily

176 Dipyridamole is an effective inhibitor of cardiovirus gr

177 Coronary vasodilation with IV dipyridamole is associated with significant reductions i

178 We report that dipyridamole is neuroprotective for a variety of rat emb

179 ring intravenous administration of saline or dipyridamole (loading dose, 0.142 mg/kg per min for 5 mi

180 After administration of dipyridamole, LV perfusion was less than half in patient

181 y examination demonstrated that CGS21680 and dipyridamole markedly enhanced bone regeneration as well

182 gh there is no proven pharmacologic therapy, dipyridamole may be promising because of its known vascu

183 of equilibrative nucleoside transporters by dipyridamole may have therapeutic potential in ischemic

184 e-to-apex perfusion gradient observed during dipyridamole MBF suggests the presence of a functional a

185 Dipyridamole MBF was attenuated only in the women with R

186 l, or aspirin combined with extended-release dipyridamole; medical-therapy group).

187 These data suggest that dipyridamole might inhibit sickling-induced fluxes of Na

188 trial compared the prognostic value of early dipyridamole MPI and standard predischarge submaximal ex

189 ltivariate predictors in patients undergoing dipyridamole MPI included only the summed stress, revers

190 Dipyridamole MPI showed better risk stratification than

191 Dipyridamole MPI very early after MI predicts early and

192 nsecutive patients underwent diagnostic rest-dipyridamole myocardial perfusion PET/CT using (82)Rb, a

193 nsecutive patients underwent diagnostic rest-dipyridamole myocardial perfusion PET/CT with (82)Rb and

194 usion before I/R (n = 25), and 4) (PPC) with dipyridamole (n = 25).

195 erwent exercise (n=11), dobutamine (n=2), or dipyridamole (n=1) myocardial perfusion single photon em

196 r technetium-99m sestamibi (n=72) and either dipyridamole (n=153) or adenosine (n=92) stress.

197 We conclude that: (1) dipyridamole nonselectively reduces PVRI, primarily thro

198 size, heart and diaphragm displacement after dipyridamole, objective quantitative misregistration of

199 This study examined the inhibition by dipyridamole of the sickling-induced fluxes of Na(+), K(

200 of A2AR abrogated the effect of CGS21680 and dipyridamole on bone regeneration.

201 To determine the effects of dipyridamole on endothelium-independent pulmonary vasodi

202 The peak effect of dipyridamole on heart rate, systemic vascular resistance

203 The effects of dipyridamole on mengovirus replication in vivo and in vi

204 Furthermore, the effect of dipyridamole on osteoblast differentiation is diminished

205 kade abrogated the effects of ticagrelor and dipyridamole on osteoclast and osteoblast differentiatio

206 To evaluate the effect of dipyridamole on pulmonary vasodilation due to the stimul

207 (0.6 mg/kg), and combined treatments (iNO + dipyridamole) on pulmonary and systemic hemodynamics.

208 of AMPK was abolished by preincubation with dipyridamole or 5-iodotubercidin.

209 omographic myocardial perfusion imaging with dipyridamole or adenosine in patients with left bundle-b

210 lockade of AICAR translocation into cells by dipyridamole or inhibition of AICAR conversion to ZMP by

211 ndings lend credence to the potential use of dipyridamole or its derivatives in prevention and/or tre

212 Dipyridamole or other antioxidant measures did not provi

213 the addition of the Ado transport inhibitor dipyridamole or the Ado kinase inhibitor 5'-amino 5'-deo

214 volume), intravenous zaprinast, intravenous dipyridamole or the combination of inhaled NO with eithe

215 e, partially by amiloride, and not at all by dipyridamole or vigabatrin.

216 The frequency of CFRs was unaffected by NO, dipyridamole or zaprinast alone.

217 Cells were treated in vitro with tacrolimus, dipyridamole, or control.

218 eceived high-dose aspirin (300 to 600 mg/d), dipyridamole, or other agents.

219 V reserve was greater during dobutamine than dipyridamole (p < 0.05).

220 d by diaphragm displacement between rest and dipyridamole (P = 0.001, CI = 0.158-0.630), body mass in

221 onfidence interval, 1.2-7.0 versus ASA 81 mg+dipyridamole; P = 0.02) and 3.4 (95% confidence interval

222 Dipyridamole (Persantine) is a clinically used vasodilat

223 ignificant effect was observed when 5 microM dipyridamole (Persantine) was added to the blood.

224 Aspirin, dipyridamole (Persantine), and thienopyridines (ticlopid

225 ur-hundred nine patients with CAD undergoing dipyridamole PET at baseline and after 2.6 +/- 1.4 y wer

226 ble coronary artery narrowing underwent rest-dipyridamole PET perfusion imaging.

227 Of 1,177 rest-dipyridamole PET perfusion studies, 252 (21.4%) had arti

228 Rest-dipyridamole PET with (82)Rb was performed on 1,034 cons

229 9 patients were randomly assigned to receive dipyridamole plus aspirin (321 patients) or placebo (328

230 Treatment with dipyridamole plus aspirin had a significant but modest e

231 Treatment with dipyridamole plus aspirin significantly prolonged the du

232 By contrast, dipyridamole plus aspirin versus aspirin alone had no ef

233 Extended-release dipyridamole plus low-dose aspirin (ERDP/ASA) prolongs p

234 ho underwent myocardial perfusion imaging by dipyridamole positron emission tomography at baseline an

235 on endogenous (basal) NO production and that dipyridamole potentiates vasodilator responses to endoth

236 Unexpectedly, application of NBTI/dipyridamole prevented the efflux of adenosine resulting

237 Because dipyridamole promotes bone regeneration by an A2AR-media

238 We studied 1252 patients with the use of dipyridamole real-time contrast echocardiography and fol

239 of myocardial perfusion (MP) imaging during dipyridamole real-time contrast echocardiography improve

240 real-time perfusion echocardiography during dipyridamole real-time contrast echocardiography provide

241 ells, and the nucleoside transport inhibitor dipyridamole reduced prodrug activity.

242 ntrations via purine transport blockade with dipyridamole regulates bone formation.

243 mbination), (2) a combination of aspirin and dipyridamole (relative risk, 0.8 [95% confidence interva

244 al segments with an endocardial MBF reserve (dipyridamole/resting MBF) of 1.5 to 2.5 (n=35) did not c

245 th PAD, treatment with aspirin alone or with dipyridamole resulted in a statistically nonsignificant

246 Compared with baseline values, dipyridamole resulted in an increase in pulmonary capill

247 eatment with the pharmacologic ENT inhibitor dipyridamole revealed elevations of hepatic adenosine le

248 ith a history of heart transplant undergoing dipyridamole rubidium-82 positron emission tomography we

249 The protective action of dipyridamole seems to be attributable to its antioxidant

250 ss mRNA corresponding to the recently cloned dipyridamole-sensitive human equilibrative nucleoside tr

251 riation in the functional expression of NBTI/dipyridamole-sensitive transporters.

252 antagonists or the adenosine uptake blocker dipyridamole showed that adenosine released endogenously

253 protective alone in basal medium, along with dipyridamole significantly enhanced long-term neuronal s

254 In Krebs extracts, dipyridamole specifically inhibited viral RNA synthesis

255 d in 22 subjects undergoing dynamic rest and dipyridamole stress (82)Rb PET studies at a 2-wk interva

256 symptomatic HCM patients at rest and during dipyridamole stress (peak) for the assessment of regiona

257 solute flow quantification at rest and after dipyridamole stress as well as the ratio of mean global

258 ocardiography and MCE both at rest and after dipyridamole stress at a mean of 9+/-2 days after admiss

259 ed with flash impulse imaging using low-dose dipyridamole stress at baseline and during hyperinsuline

260 d in 20 subjects undergoing dynamic rest and dipyridamole stress PET studies with (82)Rb and (13)N-am

261 ATED SPECT], at rest and at peak of low-dose Dipyridamole stress test, in the assessment of significa

262 Dipyridamole stress testing with myocardial perfusion im

263 With dipyridamole stress, 1) at least one defect was seen on

264 baseline, single coronary arterial stenosis, dipyridamole stress, and reactive hyperemia.

265 ogeneity analysis, or its improvement during dipyridamole stress, is a predictor of even mild stress

266 ged dynamically for 6 min at rest and during dipyridamole stress.

267 ve SPECT (201)Tl perfusion imaging following dipyridamole stress.

268 7/110 MBq) with a 1-h delay between rest and dipyridamole stress.

269 y (PET) using FDG and Rb-82 before and after dipyridamole stress; the extent of viable myocardium by

270 derwent pharmacological (752 dobutamine, 800 dipyridamole) stress echo for the evaluation of known (n

271 -atropine stress echocardiography (DASE) and dipyridamole Technetium 99-m (Tc-99m) sestamibi single p

272 We compared dipyridamole technetium-99m (Tc-99m) tetrofosmin and tha

273 ngina questionnaire for quality of life, and dipyridamole thallium stress test.

274 Patients underwent dipyridamole thallium stress tests at baseline and 3, 6

275 d trials of aspirin therapy, with or without dipyridamole that reported cardiovascular event rates.

276 pharmacologic agents (dobutamine, adenosine, dipyridamole) that have recently evolved to address thes

277 Twenty-six patients with CAD underwent both dipyridamole Tl-201 and Tc-99m tetrofosmin SPECT.

278 , erythro-9-(2-hydroxy-3-nonyl) adenine, and dipyridamole to prevent synthesis or degradation of aden

279 Dipyridamole treatment (1 mg/kg; EC50=10 muM) was associ

280 Both CGS21680 and dipyridamole treatment increased alkaline phosphatase-po

281 Dipyridamole treatment of SLE T cells significantly inhi

282 g of aspirin plus 200 mg of extended-release dipyridamole twice daily or to receive 75 mg of clopidog

283 d of other FDA approved drugs, we identified dipyridamole, used for the prevention of cerebral ischem

284 , have correlated the hemodynamic effects of dipyridamole using invasive monitoring with perfusion pa

285 ted tomography (SPECT) were performed during dipyridamole vasodilation.

286 On PET, EF during dipyridamole was 56% +/- 15% and 52% +/- 15% using the 2

287 as dependent on hematocrit, and up to 30% of dipyridamole was bound to RBC membranes at 2% hematocrit

288 RBC membrane content of dipyridamole was measured fluorometrically and correlate

289 gregation in dogs breathing NO and receiving dipyridamole was reduced by 75+/-7% (p < 0.05).

290 Myocardial blood flow responses to dipyridamole were similar in the insulin-sensitive and i

291 MRP inhibitors (NSAIDs, PDE5-i, salicylates, dipyridamole) were collected.

292 F) of 1.5 to 2.5 (n=35) did not change after dipyridamole, whereas it decreased in segments with an e

293 .5 to 2.5 showed inducible dysfunction after dipyridamole, whereas none of the segments with an endoc

294 Treatment of cells with dipyridamole, which blocks AICAR cellular uptake abolish

295 Lastly, local injection of dipyridamole, which inhibits transport of adenosine thro

296 asured the pulmonary and systemic effects of dipyridamole while the patients were breathing room air

297 ormed to investigate the interaction between Dipyridamole with unmethylated and methylated cytosine.

298 therapy (combined aspirin, clopidogrel, and dipyridamole) with that of guideline-based antiplatelet

299 oaded SS RBCs, was also partially blocked by dipyridamole, with a dose response similar to that of Na

300 PDE11A2 is sensitive to dipyridamole, with an IC(50) of 1.8 microM, and to zapri